HIMS Stock Analysis: Buy, Sell, or Hold?
HIMS - Hims & Hers Health, Inc.
$30.23
2.46 (8.85%)
▲
5d:
-0.04%
30d:
-17.86%
90d:
+10.28%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 10, 2026
6d
Smart Money Accumulation
None View Scanner →
Strength: 8.5/10
Get Alerted When HIMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: HIMS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: HIMS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.60
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$13.41
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HIMS is currently trading at $30.23, which is considered oversold relative to its 30-day fair value range of $29.89 to $36.25. The stock's valuation (Forward PE: 45.0) is in line with its historical norms (43.4). At these levels, the market is pricing in 1.3% annual earnings growth.
Technical Outlook: Technically, HIMS is in a strong uptrend. Immediate support is located at $24.24, while resistance sits at $35.85. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HIMS is in a strong uptrend. Immediate support is located at $24.24, while resistance sits at $35.85. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$29.89 -
$36.25
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.8%)
- NEUTRAL: Near Wall St target ($29.23)
- BULLISH: Expecting earnings turnaround to 1.3% growth with 3.8% revenue growth
Trading Range Analysis
30-Day Trading Range
$29.89 -
$36.25
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$24.24
Resistance Level
$35.85
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
45.03
Wall Street Target
$29.23
(+5.3%)
Revenue Growth (YoY)
3.8%
Earnings Growth (YoY)
-17.4%
Profit Margin
-0.6%
Valuation Premium vs History
+1.3% premium
PE vs Historical
45.0 vs 43.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.3%
(market-implied from PE analysis)
1-Year Target
$28.13
(+1%)
2-Year Target
$28.50
(+3%)
3-Year Target
$28.87
(+4%)
3-Yr Target (if PE normalizes)
(PE: 45→43)
PE COMPRESSION
$27.82
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 03, 2026 12:32 PM ET
Data refreshes hourly during market hours. Next update: 1:32 PM
Data refreshes hourly during market hours. Next update: 1:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HIMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Soleil Boughton
SELL
9463 shares
2026-04-20
Oluyemi Okupe
SELL
19645 shares
2026-04-20
Oluyemi Okupe
SELL
18005 shares
2026-04-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced HIMS Option Strategies
Professional options setups generated by AI based on today's HIMS price and gamma walls.
